Case Report: Transient Stress Hyperglycemia in the Patient With ST-Elevation Myocardial Infarction

Journal for Nurse Practitioners

Volumn 18, Issue 2, 2022, Pages 245-247

  Hollister Meadows, Laura ^a  

^a NONE

Author keywords

myocardial infarction; STEMI; stress hyperglycemia; type 2 diabetes

Indexed keywords

EID: 85116476979     PISSN: 15554155     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurpra.2021.09.007     Document Type: Article

References (14)

1. Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions [published correction appears in Circulation. 2012;125(8):e412. Dosage error in article text]. Circulation 124:23 (2011), e574–e651, 10.1161/CIR.0b013e31823ba622.
2. O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in Circulation. 2013;128(25):e481]. Circulation 127:4 (2013), e362–e425, 10.1161/CIR.0b013e3182742cf6.
3. Radin, M.S., Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med 29:2 (2014), 388–394, 10.1007/s11606-013-2595-x.
4. Cruikshank, N., Coronary thrombosis and myocardial infarction, with glycosuria. BMJ 1 (1931), 618–619.
5. Modan, B., Schor, S., Shani, M., Acute myocardial infarction: prognostic value of white blood cell count and blood glucose level. JAMA 233 (1975), 266–267.
6. Khalfallah, M., Abdelmageed, R., Elgendy, E., Hafez, Y.M., Incidence, predictors and outcomes of stress hyperglycemia in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention. Diab Vasc Dis Res, 17(1), 2020 1479164119883983. https://doi.org/10.1177/1479164119883983.
7. Wahab, N.N., Cowden, E.A., Pearce, N.J., et al. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?. J Am Coll Cardiol 40:10 (2002), 1748–1754, 10.1016/s0735-1097(02)02483-x.
8. Kosiborod, M., Rathore, S.S., Inzucchi, S.E., et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 111:23 (2005), 3078–3086, 10.1161/CIRCULATIONAHA.104.517839.
9. Bolk, J., van der Ploeg, T., Cornel, J.H., Arnold, A.E., Sepers, J., Umans, V.A., Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol 79:2-3 (2001), 207–214, 10.1016/s0167-5273(01)00422-3.
10. Planer, D., Witzenbichler, B., Guagliumi, G., et al. Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI trial. Int J Cardiol 167:6 (2013), 2572–2579, 10.1016/j.ijcard.2012.06.054.
11. Jialal, I., Chaudhuri, A., Targeting inflammation to reduce ASCVD in type 2 diabetes. J Diabetes Complications 33:1 (2019), 1–3, 10.1016/j.jdiacomp.2018.11.001.
12. Das, S.R., Everett, B.M., Birtcher, K.K., et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 76:9 (2020), 1117–1145, 10.1016/j.jacc.2020.05.037.
13. Xiang, B., Zhao, X., Zhou, X., Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients. Cardiovasc Diabetol, 20(1), 2021, 78, 10.1186/s12933-021-01266-x.
14. American Diabetes Association. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020 [published correction appears in Diabetes Care. 2020;43(8):1977-1978]. Diabetes Care 43:suppl 1 (2020), S111–S134, 10.2337/dc20-S010.